Sun Pharma secures DCGI nod for generic semaglutide; plans Noveltreat launch post patent expiry

Sun Pharmaceutical Industries announced regulatory clearance from the Drugs Controller General of India (DCGI) for its generic semaglutide injection. Semaglutide, a GLP‑1 receptor agonist, is used for glycemic control in type 2 diabetes and for chronic weight management when combined with diet and physical activity. Sun Pharma indicated that commercial rollout under the brand name Noveltreat will occur after patent expiry, aligning market entry with compliance and supply readiness.

Key highlights

Regulatory approval:

• DCGI has approved Sun Pharma’s generic semaglutide injection for manufacture and marketing in India.

Launch timing:

• Product to be introduced as Noveltreat following patent expiry, ensuring adherence to intellectual property obligations.

Therapeutic scope:

• Addresses type 2 diabetes management and supports medically supervised weight reduction protocols.

Market outlook:

• Expands access to GLP‑1 therapies amid strong demand and constrained global supply; potential pricing competition expected.

Operational focus:

• Emphasis on quality, pharmacovigilance, and scaled manufacturing to meet anticipated uptake across hospitals and clinics.

Sun Pharma’s strategy balances regulatory compliance with market opportunity, positioning Noveltreat to compete in a fast‑growing therapeutic class once patent barriers lift.

Sources: Sun Pharmaceutical Industries Ltd; Drugs Controller General of India (DCGI).